Just a few neoantigens may be enough for T cells to control prostate cancer

In a phase II clinical trial, 29 patients with metastatic castration-resistant prostate cancer were treated with ipilimumab after tumor resection. Median radiographic PFS was 3 months, median clinical PFS was 2 months, and median OS was 24 months. Best ORR was stable disease in 37% of patients. In the “favorable” cohort (PFS>6 months, median OS of 45 months), pretreatment tumors had increased CD8+ T cell density and IFNγ response gene signature compared with the “unfavorable” cohort (PFS<6 months, median OS of 5 months), while TMB was similar between cohorts. In post-treatment PBMCs, CD8+ T cell responses to PSMA, PAP, and/or neoantigens were found in 4 patients, all of which were in the favorable cohort.

Engineered T cell therapy for viral and non-viral epithelial

Developing neoantigen-targeted T cell–based treatments for solid

Frontiers Combining energy-based focal ablation and immune

Frontiers Moving on From Sipuleucel-T: New Dendritic Cell

Immunity, Hypoxia, and Metabolism–the Ménage à Trois of Cancer

IJMS, Free Full-Text

PDF) Clonal Neoantigen: Emerging “Mechanism-based” Biomarker of

Neoantigen-targeted CD8+ T cell responses with PD-1 blockade

Photodynamic therapy combined with immunotherapy: Recent advances

IJMS, Free Full-Text

Frontiers T Cell Dysfunction and Exhaustion in Cancer

What is neoantigen-based therapy?

Engineering neoantigen vaccines to improve cancer personalized

Deciphering the mechanisms of action of progesterone in breast cancer

La Ligue contre le cancer (@laliguecancer) / X

Groupe Francophone Thrombose et Cancer

Collectif Activité physique et cancer

Pourquoi faire 25 ou 33 séances de radiothérapie?